Join Calidi Biotherapeutics for an Exclusive Investor Experience
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) invites investors to participate in an exciting online webinar scheduled for November. This unique opportunity will take place on November 19 at 1:15 p.m. PT and will be hosted by RedChip Companies, bringing together key industry insights and updates from Calidi’s CEO, Eric Poma, Ph.D.
What to Expect from the Webinar
This exclusive event promises to deliver valuable information about Calidi’s innovative approach to precision genetic medicine. Calidi’s proprietary RedTail platform is engineered to accomplish a remarkable feat: delivering genetic medicines directly to difficult-to-reach metastatic tumor sites. By circumventing immune detection, this systemically delivered viral therapy ensures that it reaches its target effectively, enhancing the anti-tumor immune response.
Preclinical Findings Show Promise
Recent data presented at the Society of Immunotherapy for Cancer (SITC) annual conference highlights the RedTail platform's ability to evade immune clearance and replicate within tumor cells at metastatic locations. This advance is pivotal, proving that the platform can express genetic medicines with concentrations comparable to localized methods while minimizing systemic exposure. Such promising findings will serve as a backbone for Calidi's market strategy in the expansive oncology market projected to surpass $560 billion by 2033.
What is the RedTail Platform?
The RedTail platform, an engineering marvel within Calidi’s portfolio, utilizes a non-integrating viral backbone that allows it to deliver multiple genetic payloads. This capability grants it the potential to revolutionize the treatment landscape for various cancers, including non-small cell lung cancer and ovarian cancer, where unmet medical needs are pressing.
Advancing Towards IND Filing
As Calidi Biotherapeutics strides towards its Investigational New Drug (IND) filing by the end of 2026, stakeholders can expect to hear updates regarding clinical progress and future trials during the webinar. The Company has reported a solid financial foundation with decreased debt, increased cash reserves, and stringent cost controls for General and Administrative expenditures, creating optimism for future endeavors.
A Chance for Engagement
One of the features that makes this webinar particularly appealing is the live Q&A session that will occur after Eric Poma's presentation. This interaction will allow attendees to pose questions, fostering a deeper understanding of Calidi’s operations and future goals.
Investors interested in participating can register for the free webinar online. Questions may also be submitted in advance to ensure a comprehensive discussion during the event.
About Calidi Biotherapeutics
Calidi Biotherapeutics stands at the forefront of clinical-stage immuno-oncology. With a focus on developing targeted therapies capable of delivering genetic medicines, the Company’s RedTail platform shines as the centerpiece of its innovation strategy. This platform's ability to evade immune detection while delivering therapeutic agents directly to metastatic sites positions Calidi as a leader in the biotech space.
Whether aiming to treat various cancer types or focusing on localized administration methods, Calidi's commitment to tackling some of the toughest challenges in cancer therapy is evident. The promise of the Company’s innovations brings hope not only to patients but also to investors seeking to support a transformative approach within the healthcare sector.
Frequently Asked Questions
What is the purpose of the upcoming webinar?
The webinar aims to enlighten investors on Calidi Biotherapeutics’ advancements in genetic therapies and provide insights into the company’s innovative RedTail platform.
Who is leading the presentation during the webinar?
Eric Poma, Ph.D., the CEO of Calidi Biotherapeutics, will present and discuss the company’s revolutionary approaches.
How can I register for the webinar?
Interested participants can register for the free webinar via Calidi’s official registration link.
What updates can attendees expect regarding Calidi's projects?
Attendees will receive insights on the ongoing developments related to the RedTail platform, including updates towards IND filing and clinical trials.
How can I submit questions for the Q&A session?
Questions can be pre-submitted online or asked live during the event to engage directly with the leadership team.
